valproic acid has been researched along with Lymphoma, B-Cell in 2 studies
Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.
valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.
Lymphoma, B-Cell: A group of heterogeneous lymphoid tumors generally expressing one or more B-cell antigens or representing malignant transformations of B-lymphocytes.
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Shimizu, R | 1 |
Kikuchi, J | 1 |
Wada, T | 1 |
Ozawa, K | 1 |
Kano, Y | 1 |
Furukawa, Y | 1 |
Zain, J | 1 |
Rotter, A | 1 |
Weiss, L | 1 |
Forman, S | 1 |
Kirschbaum, MH | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
The Efficacy and Safety of Chidamide Combined With VDDT Regimen(Vinorelbine,Liposomal Doxorubicin,Dexamethasone and Thalidomide) in Relapse and Refractory Patients With Diffuse Large B Cell Lymphoma[NCT02733380] | Phase 2 | 20 participants (Anticipated) | Interventional | 2016-05-31 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 other studies available for valproic acid and Lymphoma, B-Cell
Article | Year |
---|---|
HDAC inhibitors augment cytotoxic activity of rituximab by upregulating CD20 expression on lymphoma cells.
Topics: Acetylation; Animals; Antibiotics, Antineoplastic; Antibodies, Monoclonal; Antibodies, Monoclonal, M | 2010 |
Valproic acid monotherapy leads to CR in a patient with refractory diffuse large B cell lymphoma.
Topics: Antineoplastic Agents; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Lymphoma, | 2007 |